Form 8-K - Current report:
SEC Accession No. 0001493152-25-018054
Filing Date
2025-10-14
Accepted
2025-10-14 17:25:12
Documents
14
Period of Report
2025-10-07
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K form8-k.htm   iXBRL 8-K 38644
2 EX-10.1 ex10-1.htm EX-10.1 368644
3 EX-10.2 ex10-2.htm EX-10.2 102303
  Complete submission text file 0001493152-25-018054.txt   774505

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE ppcb-20251007.xsd EX-101.SCH 3011
5 XBRL LABEL FILE ppcb-20251007_lab.xml EX-101.LAB 34239
6 XBRL PRESENTATION FILE ppcb-20251007_pre.xml EX-101.PRE 22356
16 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3662
Mailing Address 302/6 BUTLER STREET CAMBERWELL, VICTORIA C3 3124
Business Address 302/6 BUTLER STREET CAMBERWELL, VICTORIA C3 3124 61-03-9882-0780
Propanc Biopharma, Inc. (Filer) CIK: 0001517681 (see all company filings)

EIN.: 330662986 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 8-K | Act: 34 | File No.: 001-42806 | Film No.: 251392713
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)